Literature DB >> 19258502

Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer.

Stephan Singer1, Mona Malz, Esther Herpel, Arne Warth, Michaela Bissinger, Martina Keith, Thomas Muley, Michael Meister, Hans Hoffmann, Roland Penzel, Georg Gdynia, Volker Ehemann, Philipp Albert Schnabel, Ruprecht Kuner, Peter Huber, Peter Schirmacher, Kai Breuhahn.   

Abstract

Dynamic instability of the microtubule network modulates processes such as cell division and motility, as well as cellular morphology. Overexpression of the microtubule-destabilizing phosphoprotein stathmin is frequent in human malignancies and represents a promising therapeutic target. Although stathmin inhibition gives rise to antineoplastic effects, additional and functionally redundant microtubule-interacting proteins may attenuate the efficiency of this therapeutic approach. We have systematically analyzed the expression and potential protumorigenic effects of stathmin family members in human non-small cell lung cancer (NSCLC). Both stathmin and stathmin-like 3 (SCLIP) were overexpressed in adenocarcinoma as well as squamous cell carcinoma (SCC) tissues and induced tumor cell proliferation, migration, and matrix invasion in respective cell lines. Accordingly, reduced stathmin and SCLIP levels affected cell morphology and were associated with a less malignant phenotype. Combined inhibition of both factors caused additive effects on tumor cell motility, indicating partial functional redundancy. Because stathmin and SCLIP expression significantly correlated in NSCLC tissues, we searched for common upstream regulators and identified the far upstream sequence element-binding protein-1 (FBP-1) as a pivotal inducer of several stathmin family members. Our results indicate that the coordinated overexpression of microtubule-destabilizing factors by FBP-1 is a critical step to facilitate microtubule dynamics and subsequently increases proliferation and motility of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258502     DOI: 10.1158/0008-5472.CAN-08-3338

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.

Authors:  Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

2.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

3.  FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.

Authors:  Updesh Dixit; Ashutosh K Pandey; Zhihe Liu; Sushil Kumar; Matthew B Neiditch; Kenneth M Klein; Virendra N Pandey
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.

Authors:  C M Fife; S M Sagnella; W S Teo; S T Po'uha; F L Byrne; Y Y C Yeap; D C H Ng; T P Davis; J A McCarroll; M Kavallaris
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

5.  Distinct germ line polymorphisms underlie glioma morphologic heterogeneity.

Authors:  Robert B Jenkins; Margaret R Wrensch; Derek Johnson; Brooke L Fridley; Paul A Decker; Yuanyuan Xiao; Thomas M Kollmeyer; Amanda L Rynearson; Stephanie Fink; Terri Rice; Lucie S McCoy; Chandralekha Halder; Matthew L Kosel; Caterina Giannini; Tarik Tihan; Brian P O'Neill; Daniel H Lachance; Ping Yang; Joseph Wiemels; John K Wiencke
Journal:  Cancer Genet       Date:  2011-01

6.  The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.

Authors:  Aishwarya G Jacob; Ravi K Singh; Fuad Mohammad; Thomas W Bebee; Dawn S Chandler
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

7.  Comparison of lung cancer cell lines representing four histopathological subtypes with gene expression profiling using quantitative real-time PCR.

Authors:  Takashi Watanabe; Tomohiro Miura; Yusuke Degawa; Yuna Fujita; Masaaki Inoue; Makoto Kawaguchi; Chie Furihata
Journal:  Cancer Cell Int       Date:  2010-01-21       Impact factor: 5.722

8.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

9.  Far Upstream Element Binding Protein Plays a Crucial Role in Embryonic Development, Hematopoiesis, and Stabilizing Myc Expression Levels.

Authors:  Weixin Zhou; Yang Jo Chung; Edgardo R Parrilla Castellar; Ying Zheng; Hye-Jung Chung; Russell Bandle; Juhong Liu; Lino Tessarollo; Eric Batchelor; Peter D Aplan; David Levens
Journal:  Am J Pathol       Date:  2016-01-14       Impact factor: 4.307

Review 10.  Far upstream element binding protein 1: a commander of transcription, translation and beyond.

Authors:  J Zhang; Q M Chen
Journal:  Oncogene       Date:  2012-08-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.